Clinuvel Pharmaceuticals (ASX:CUV) Valuation After EMA Year Round SCENESSE Approval And Half Year Earnings [Yahoo! Finance]
CLINUVEL PHARMS LTD S/ADR (CLVLY)
NASDAQ:AMEX Investor Relations:
clinuvel.com/investors
Company Research
Source: Yahoo! Finance
Clinuvel Pharmaceuticals (ASX:CUV) has moved back into focus after the European Medicines Agency approved year round use of SCENESSE for erythropoietic protoporphyria, alongside fresh half year earnings that give investors more to assess. See our latest analysis for Clinuvel Pharmaceuticals. The latest EMA decision and half year numbers land after a tougher run for shareholders, with a 1 day share price return of -9.33% and a year to date share price return of -21.24% indicating declines, while the 5 year total shareholder return of -55.46% points to fading longer term momentum. If this regulatory update has you reassessing your biotech exposure, it could be a good moment to broaden your search with our 10 healthcare AI stocks sourced from the Simply Wall St screener. With the share price down over multiple time frames but analysts and internal models indicating a large discount to estimated value, the key question is whether Clinuvel is now mispriced or whether the market is
Show less
Read more
Impact Snapshot
Event Time:
CLVLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLVLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLVLY alerts
High impacting CLINUVEL PHARMS LTD S/ADR news events
Weekly update
A roundup of the hottest topics
CLVLY
News
- High Growth Tech Stocks To Watch In January 2026 [Yahoo! Finance]Yahoo! Finance
- Will VLRX-L Preclinical Dosing Signal a New Pipeline Chapter for Clinuvel Pharmaceuticals (ASX:CUV) Narrative [Yahoo! Finance]Yahoo! Finance
- Assessing Clinuvel Pharmaceuticals' Valuation As VLRX L Enters Its First Preclinical Dosing Study [Yahoo! Finance]Yahoo! Finance
- Exploring Three High Growth Tech Stocks In Australia [Yahoo! Finance]Yahoo! Finance
- Artrya And 2 Other High Growth Tech Stocks With Potential In Australia [Yahoo! Finance]Yahoo! Finance